Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Schizophrenia – Unmet Need – Unmet Need – Treatment Resistant Schizophrenia (US/EU)

Login to access report north_east
Contact sales account_box

Most psychiatrists define TRS as a lack of response to at least two treatment changes. Currently, clozapine is the only approved drug for this condition, but its use is limited due to safety concerns associated with a black box warning, poor tolerability, and the need for regular blood monitoring. Additionally, a significant proportion of TRS patients fail to respond adequately to clozapine, leaving them with limited treatment options. The late-stage pipeline for TRS is sparse. Notably, Newron Pharmaceuticals is investigating evenamide as an add-on treatment to antipsychotics for TRS patients. The drug has shown positive efficacy and safety in Phase 2. With up to 30% of drug-treated schizophrenia patients being treatment-resistant, this patient segment represents a substantial commercial opportunity for safe and effective treatments.

Questions answered

  • Which clinical/nonclinical attributes for a therapy will influence psychiatrists’ treatment decisions for TRS patients?
  • How do psychiatrists rate the performance of key current therapies on treatment drivers and goals for TRS?
  • What are the prevailing areas of unmet need in TRS?
  • What are the key opportunities for drug development in TRS?

Product description

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

  • Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
  • Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
  • Analyze market scenarios for different target product profiles using the TPP Simulator.

Key feature

Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European psychiatrists fielded in February 2025

Key companies: Otsuka Pharmaceutical, Lundbeck, Eli Lilly, Johnson & Johnson Innovative Medicine, AbbVie, Recordati

Key drugs: Clozapine, aripiprazole, risperidone, paliperidone palmitate, olanzapine, brexpiprazole, cariprazine

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
north_east
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…
north_east
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
north_east
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…
north_east
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east